Market closed
Aziyo Biologics/$ELUT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aziyo Biologics
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
Ticker
$ELUT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
51
Website
Aziyo Biologics Metrics
BasicAdvanced
$95M
-
-$1.86
0.86
-
Price and volume
Market cap
$95M
Beta
0.86
52-week high
$3.46
52-week low
$1.87
Average daily volume
44K
Financial strength
Current ratio
0.692
Quick ratio
0.411
Long term debt to equity
-48.861
Total debt to equity
-52.557
Interest coverage (TTM)
-5.08%
Management effectiveness
Return on assets (TTM)
-38.15%
Return on equity (TTM)
127.57%
Valuation
Price to revenue (TTM)
2.779
Price to book
-1.77
Price to tangible book (TTM)
-1.5
Price to free cash flow (TTM)
-2.906
Growth
Revenue change (TTM)
-1.50%
Earnings per share change (TTM)
-10.50%
3-year revenue growth (CAGR)
-19.88%
3-year earnings per share growth (CAGR)
-7.93%
Aziyo Biologics News
AllArticlesVideos
Elutia to Participate in Chardan's Trending Issues in Drug Development Conference Series on April 29
GlobeNewsWire·5 days ago
Elutia Initiates EluPro™ Registry Study Designed to Generate Evidence Supporting the Use of EluPro in Real-World Clinical Practice
GlobeNewsWire·6 days ago
Elutia Confirms No Material Impact from Global Tariffs
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aziyo Biologics stock?
Aziyo Biologics (ELUT) has a market cap of $95M as of April 27, 2025.
What is the P/E ratio for Aziyo Biologics stock?
The price to earnings (P/E) ratio for Aziyo Biologics (ELUT) stock is 0 as of April 27, 2025.
Does Aziyo Biologics stock pay dividends?
No, Aziyo Biologics (ELUT) stock does not pay dividends to its shareholders as of April 27, 2025.
When is the next Aziyo Biologics dividend payment date?
Aziyo Biologics (ELUT) stock does not pay dividends to its shareholders.
What is the beta indicator for Aziyo Biologics?
Aziyo Biologics (ELUT) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.